Analogues of glucagon-like peptide 1 and obesity, what indications and what results? (notice n° 750365)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03076cam a2200361 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250123094237.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Bergua, Gérard |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Analogues of glucagon-like peptide 1 and obesity, what indications and what results? |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 60 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | En France le surpoids concerne 49 % des adultes et l’obésité 17 % [1]. Sa prévalence augmente dans l’ensemble de la population et beaucoup plus rapidement chez l’enfant. Les données chez les adolescents de classe de 3e montrent une augmentation du surpoids et de l’obésité respectivement de 20 % et 5,4 % chez les filles et 17 % et 4,7 % chez les garçons [2]. Plusieurs types d’intervention sont proposés pour lutter contre l’obésité, interventions liées au mode de vie, lutte contre la sédentarité, contrôle de l’alimentation, prescriptions médicamenteuses. Les médicaments anti-obésité ont montré de grandes variabilités dans leur efficacité en termes de perte de poids, allant de 5 % à 12 % dans les divers essais contrôlés randomisés et selon les contextes cliniques [3]. Deux médicaments analogues du glucagon-like peptide 1, indiqués dans le traitement du diabète de type 2 insuffisamment contrôlé, le semaglutide et le liraglutide, sont utilisés chez des patients adultes non-diabétiques obèses ou en surpoids, pour quel bénéfice et quels inconvénients ? |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | In France, 49% of adults are overweight and 17% are obese [1]. Its prevalence is increasing in the entire population and much more rapidly in children. Data among 3rd grade adolescents show an increase in overweight and obesity of 20% and 5.4% respectively among girls and 17% and 4.7% among boys [2]. Several types of intervention are proposed to combat obesity, lifestyle interventions, combating a sedentary lifestyle, diet control, medication prescriptions. Anti-obesity drugs have shown great variability in their effectiveness in terms of weight loss, ranging from 5% to 12% in various randomized controlled trials and depending on clinical contexts [3]. Two Glucagon-like peptide1 analog drugs, indicated in the treatment of insufficiently controlled type 2 diabetes, semaglutide and liraglutide, are used in obese or overweight non-diabetic adult patients. For what benefit and what disadvantages? |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | glucagon-like peptide 1 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | liraglutide |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | sémaglutide |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | surpoids |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | obésité |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | glucagon-like peptide 1 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | liraglutide |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | obesity |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | overweight |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | semaglutide |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dumoulin, Marc |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hagiu, Dragos-Paul |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Le Noc, Yves |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Scali, Claude |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Drahi, Éric |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Steyer, Élisabeth |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Médecine | 20 | 4 | 2024-04-12 | p. 155-159 | 1777-2044 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-medecine-2024-4-page-155?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-medecine-2024-4-page-155?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux